Vunakizumab (SHR-1314), a subcutaneously administered anti-IL-17A IgG1/κ antibody used in the treatment of psoriasis and ankylosing spondylitis, entered a TED trial but was discontinued early for commercial reasons [88]. Here, IL17A is linked to psoriasis.